New EU Filings Include Tibsovo Resubmission, Pegunigalsidase & Daprodustat
Executive Summary
Servier is trying again with Tibsovo in the EU, while Protalix is using June 2021 data to support its filing for pegunigalsidase, which the US regulator turned down last April.
You may also be interested in...
New EU Filings
Sugemalimab, from CStone Pharmaceuticals/EQRx, for use in combination with chemotherapy as first-line treatment for metastatic non-small cell lung cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Aprocitentan, Idorsia/Janssen Biotech’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with resistant hypertension, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.